34 results on '"Katz, Matthew H G"'
Search Results
2. Addition of metastasis-directed therapy to standard-of-care systemic therapy for oligometastatic pancreatic ductal adenocarcinoma (EXTEND): Results of a multicenter, randomized phase II trial.
3. A novel classification of small bowel adenocarcinoma based on a hidden genome classifier: A multi-institutional study.
4. Postoperative complications following neoadjuvant therapy and surgery in a phase 2 borderline resectable pancreatic cancer clinical trial (Alliance A021501).
5. Frequency and oncologic outcomes of KRAS mutations in circulating tumor DNA of patients with pancreatic ductal adenocarcinoma.
6. Randomized multicenter phase Ib/II study of neoadjuvant chemoradiation therapy (CRT) alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic cancer.
7. Alliance A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated radiation therapy (RT) for borderline resectable (BR) adenocarcinoma of the pancreas.
8. Pattern of recurrence after curative resection of stage I-III duodenal adenocarcinoma.
9. The clinical utility of the 2017 Fukuoka Guidelines and 2015 American Gastroenterological Association Guidelines for the management of intraductal papillary mucinous neoplasms.
10. The effect of antibiotic use on survival of patients with resected pancreatic ductal adenocarcinoma.
11. Adaptive Dose Escalation Trial of Stereotactic Body Radiation Therapy (SBRT) in combination with GC4419 in pancreatic cancer.
12. New onset diabetes as a predictive factor of focal lesions in the pancreas in a high-risk screening program.
13. Early outcomes of a high-risk cohort in pancreatic cancer surveillance.
14. High prevalence of hereditary cancer syndromes and outcomes in adults with early-onset pancreatic cancer.
15. Neoadjuvant FOLFIRINOX in patients with (borderline) resectable pancreatic cancer: A systematic review and patient-level meta-analysis.
16. Discovery and validation of a quantitative, stromal-associated imaging biomarker of pancreatic ductal adenocarcinoma (PDAC).
17. First line gemcitabine and nab-paclitaxel chemotherapy for localized pancreatic ductal adenocarcinoma.
18. Alliance for clinical trials in oncology trial A021501: Preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas.
19. Preliminary safety data from a randomized multicenter phase Ib/II study of neoadjuvant chemoradiation therapy (CRT) alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic cancer.
20. Tumor interface stability on CT imaging is an early marker of response to cytotoxic therapy in pancreatic ductal adenocarcinoma.
21. Larger size extracellular vesicle as early biomarker in patients with metastatic pancreatic cancer.
22. Impact of race on surgical management of pancreatic neuroendocrine tumors.
23. A retrospective single institution review of 90 pancreatic adenosquamous cancer (PASC) patients (pts).
24. A randomized multicenter phase Ib/II study to assess the safety and the immunological effect of chemoradiation therapy (CRT) in combination with pembrolizumab (anti-PD1) to CRT alone in patients with resectable or borderline resectable pancreatic cancer.
25. Preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by chemoradiation (CRT) for borderline resectable (BLR) pancreatic cancer (PDAC): Initial results from Alliance Trial A021101.
26. Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.
27. Prevalence of germline variants in patients with pancreatic neuroendocrine tumors.
28. Phase II study of preoperation mFOLFIRINOX and chemoradiation for high-risk resectable and borderline resectable pancreatic adenocarcinoma.
29. Effect of dose-escalation of IMRT for unresectable pancreatic cancer 1 cm away from the luminal mucosa on long-term survival.
30. Overall survival and clinical characteristics in BRCA mutation carriers with stage I/II pancreatic cancer (PC).
31. The effect of anti-IGF1 therapy on muscle mass in metastatic pancreatic cancer.
32. Salmonella typhimurium A1-R effectively targets human-patient pancreatic tumorgrafts in nude mice.
33. Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
34. Potentially Curable Pancreatic Adenocarcinoma: ASCO Clinical Practice Guideline Update.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.